Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

20 Sep 2013 10:21

UPDATE 1-Japan approves three new lung drugs from Western firms

* Approvals for inhaled drugs from GSK, Novartis, SkyePharma * SkyePharma shares up more than 15 percent (Adds detail on Novartis drug, SkyePharma share price jump) LONDON, Sept 20 (Reuters) - Japan has approved three new lung drugs from Western companies, underscoring how the world

Read more
20 Sep 2013 07:42

Japan approves lung drugs from GSK/Theravance and SkyePharma

LONDON, Sept 20 (Reuters) - GlaxoSmithKline and Theravance's new inhaled lung drug Relvar has been approved in Japan, a day after winning a positive recommendation in Europe. The Japanese Ministry of Health, Labour and Welfare also approved Skyepharma's Flutiform lung treatment, which will

Read more
20 Sep 2013 07:28

GlaxoSmithKline Treatments Given Positive Opinion In Europe, Approved in Japan

Read more
19 Sep 2013 18:10

UPDATE 1-GSK, Theravance lung drug Relvar wins European green light

LONDON, Sept 19 (Reuters) - GlaxoSmithKline and Theravance's new inhaled lung drug Relvar has been recommended for approval in Europe, Britain's biggest drugmaker said on Thursday. The green light from the European Medicines Agency follows approval for the product in May in the United State

Read more
19 Sep 2013 17:38

GSK, Theravance lung drug Relvar wins European green light

LONDON, Sept 19 (Reuters) - GlaxoSmithKline and Theravance's new inhaled lung drug Relvar has been recommended for approval in Europe, Britain's biggest drugmaker said on Thursday. The green light from the European Medicines Agency follows approval for the product in May in the United State

Read more
19 Sep 2013 13:37

GSK signs $196 mln U.S. anthrax treatment deal

LONDON, Sept 19 (Reuters) - Britain's GlaxoSmithkline said it had signed a new four-year deal worth $196 million to supply the U.S. government with its inhalation anthrax treatment, raxibacumab, in case of a potential bio-terrorist attack. GSK said on Thursday that it would supply 60,000 d

Read more
18 Sep 2013 15:35

MARKET PULSE- FedEx, Tesla, Atossa, Adobe, Tower Group, Benefitfocus

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) Sept 18 (Reuters) - Some U.S. stocks on the move on Wednesday: WALL ST FLAT, INVESTORS

Read more
18 Sep 2013 14:53

MARKET PULSE- FedEx, Tesla, Atossa, Adobe, Tower Group

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) Sept 18 (Reuters) - Some U.S. stocks on the move on Wednesday: WALL ST FLAT, INVESTORS

Read more
18 Sep 2013 13:47

MARKET PULSE- FedEx, Tesla, Five Below, Adobe, Tower Group

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) Sept 18 (Reuters) - Some U.S. stocks on the move on Wednesday: WALL STREET OPENS FLAT

Read more
18 Sep 2013 13:43

ChemoCentryx says partner GSK returns rights to bowel disease drug

Sept 18 (Reuters) - ChemoCentryx Inc said partner GlaxoSmithKline Plc returned the rights to its inflammatory bowel disease drug, the company's lead product candidate. ChemoCentryx shares fell 4 percent in early trading on the Nasdaq. The drug, vercirnon, was being tested by GSK in fo

Read more
18 Sep 2013 13:21

MARKET PULSE- Apple, FedEx, Tesla, Aruba, Five Below, Adobe

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) Sept 18 (Reuters) - Some U.S. stocks to watch on Wednesday: FUTURES INCH HIGHER AHEAD

Read more
18 Sep 2013 12:53

MARKET PULSE- Apple, FedEx, Tesla, Dollar Tree, Five Below, Adobe

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) Sept 18 (Reuters) - Some U.S. stocks to watch on Wednesday: FUTURES INCH HIGHER AHEAD

Read more
18 Sep 2013 11:58

MARKET PULSE- Apple, Fedex, Tesla, Dollar Tree, Five Below, Adobe

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s) Sept 18 (Reuters) - Some U.S. stocks to watch on Wednesday: FUTURES EDGE UP AHEAD OF FED DECISION U.S. stock index futures edged higher on Wednesday ah

Read more
18 Sep 2013 10:40

MARKET PULSE- Tesla, Dollar Tree, Five Below, Adobe

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s) Sept 18 (Reuters) - Some U.S. stocks to watch on Wednesday: ** ADOBE SYSTEMS INC, Tuesday close $48.14, up 6 pct after market The company, known for it

Read more
18 Sep 2013 06:36

AstraZeneca looks for new heart drug approval by next May

LONDON, Sept 18 (Reuters) - U.S. regulators have accepted an experimental fish oil-based heart drug from AstraZeneca for review and will make a decision on whether to approve it by next May. Epanova, for treating people with very high levels of fatty triglycerides in their blood, was devel

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.